Treatment strategies for nitroimidazole-refractory giardiasis: a systematic review

J Travel Med. 2022 Jan 17;29(1):taab120. doi: 10.1093/jtm/taab120.

Abstract

Rationale for review: Giardiasis is one of the most common human protozoal infections worldwide. First-line therapy of giardiasis includes nitroimidazole antibiotics. However, treatment failure with nitroimidazoles is increasingly reported, with up to 45% of patients not responding to initial treatment. There is no clear consensus on the approach to the management of nitroimidazole-refractory giardiasis. This systematic review aims to summarize the literature on pharmacotherapy for nitroimidazole-refractory giardiasis.

Methods: We conducted a systematic review of the literature to determine the optimal management strategies for nitroimidazole-refractory giardiasis. We searched Pubmed/MEDLINE, Embase and Cochrane library using the following search terms 'Giardia' AND 'treatment failure' OR 'refractory giardia' OR 'resistant giardia' with date limits of 1 January 1970 to 30 June 2021. We included all reports on humans, which described clinical outcomes of individuals with treatment refractory giardiasis, including case series and case reports. A descriptive synthesis of the data was conducted with pooling of data for interventions.

Key findings: Included in this review were five prospective studies, three retrospective studies, seven case series and nine case reports. Across these reports, a wide heterogeneity of treatment regimens was employed, including retreatment with an alternative nitroimidazole, combination therapy with a nitroimidazole and another agent and monotherapy with non-nitroimidazole regimens, including quinacrine, paromomycin and nitazoxanide. Retreatment with a nitroimidazole was not an effective therapy for refractory giardiasis. However, treatment with a nitroimidazole in combination with albendazole had a cure rate of 66.9%. In the included studies, quinacrine monotherapy was administered to a total of 179 patients, with a clinical cure rate of 88.8%. Overall, quinacrine was fairly well tolerated.

Conclusions: Reports on the treatment of nitroimidazole-refractory giardiasis demonstrate a heterogeneous approach to treatment. Of these, quinacrine appeared to be highly effective, though more data on its safety are needed.

Keywords: Giardia; albendazole; diarrhoea; metronidazole; nitroimidazole; quinacrine; treatment.

Publication types

  • Systematic Review

MeSH terms

  • Antiprotozoal Agents* / therapeutic use
  • Giardia lamblia*
  • Giardiasis* / drug therapy
  • Humans
  • Metronidazole / therapeutic use
  • Nitroimidazoles* / therapeutic use
  • Prospective Studies
  • Quinacrine / adverse effects
  • Quinacrine / therapeutic use
  • Retrospective Studies

Substances

  • Antiprotozoal Agents
  • Nitroimidazoles
  • Metronidazole
  • Quinacrine